Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data
Recent analyses have suggested a possible negative impact of prior autologous stem cell transplantation on outcomes with idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma. Our registry-based analysis of >800 ide-cel recipients did not identify any such association.
Authors
- Jordan Gauthier (ORCID: https://orcid.org/0000-0002-5769-8409)
- Rahul Kumar Banerjee (ORCID: https://orcid.org/0000-0003-3781-5441)
- Andrew J. Portuguese (ORCID: https://orcid.org/0000-0003-1010-4578)
- Christy Khouderchah (ORCID: https://orcid.org/0000-0001-8842-5043)
- Othman Salim Akhtar (ORCID: https://orcid.org/0000-0003-1673-9670)
- Emily C. Liang (ORCID: https://orcid.org/0000-0001-5790-4770)
- Madhav V. Dhodapkar (ORCID: https://orcid.org/0000-0002-8249-5988)
Institutions
- University of Washington (US)
- Medical College of Wisconsin (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Blood
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1182/blood.2025031426
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00